$CLDI News

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Calidi Biotherapeutics Receives NYSE American Non-Compliance Notice

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

Calidi Biotherapeutics Announces Registered Direct Offering 1,025,640 Shares At $1.17 Per Share

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Presents New Data On CLD-401 Program That It Expects To Enter Clinic In Q1 Of 2027 And In Situ T-Cell Engager Program, At 2026 AACR D3 Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

Calidi Biotherapeutics Presents Data On Its Approach Of Simultaneously Activating T-cells While Inducing Expression Of T-Cell Engagers Specifically In Situ In Tumor Microenvironment

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies

Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9